Suven Life Sciences (Suven) has secured the grant of four product patents, one each from Australia, Canada, Korea and New Zealand corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2026, 2027 and 2028.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
With these new patents, the company has a total of fifteen granted patents from Australia, nine from Canada, eight from Korea and thirteen granted patents from New Zealand. These granted patents are exclusive intellectual property of the company and are achieved through the internal discovery research efforts. The products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
